Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organon & Co. (NY: OGN )

22.07 +0.44 (+2.03%)
Official Closing Price Updated: 7:00 PM EDT, Jul 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,862,912
Open 21.85
Bid (Size) 21.86 (1)
Ask (Size) 22.15 (40)
Prev. Close 21.63
Today's Range 21.54 - 22.16
52wk Range 10.84 - 24.08
Shares Outstanding N/A
Dividend Yield 5.07%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
From Organon & Co.
Via Business Wire
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
These exchange-traded funds should keep the income flowing in regularly. 
Via The Motley Fool
Topics ETFs

Performance

YTD
+50.03%
+50.03%
1 Month
+6.16%
+6.16%
3 Month
+19.82%
+19.82%
6 Month
+31.06%
+31.06%
1 Year
-0.99%
-0.99%

More News

Read More
High Dividend 50: Organon & Co.
Via Talk Markets
Value Investing Is Back! 3 Stocks With Strong Fundamentals to Buy Now
Via InvestorPlace
Thursday Is Your Last Chance To Buy Organon Before The Dividend Payout
Via Benzinga
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Via The Motley Fool
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
From Organon & Co.
Via Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
Via Benzinga
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Organon Announces Proposed $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Organon Beats On Q1, Women's Health Leads the Charge
Via Benzinga
OGN Stock Earnings: Organon Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Organon Reports Results for the First Quarter Ended March 31, 2024
From Organon & Co.
Via Business Wire
7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024
Via InvestorPlace
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
Via InvestorPlace
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
From Organon & Co.
Via Business Wire
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
From Organon & Co.
Via Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Turn $500 into a Fortune: 3 Top Stock Picks for March’s Million-Dollar Rally
Via InvestorPlace
5 Value Stocks In The Healthcare Sector
Via Benzinga
Drug Maker Organon Stock Scores Relative Strength Upgrade
Via Investor's Business Daily
Under the Radar: 3 Overlooked Stocks Ready to Dominate the Market
Via InvestorPlace
New York Attorney General Urges FDA Action On Widely Used Asthma Drug's Concerns Over Pediatric Safety
Via Benzinga
Exposures Product Safety
Don't Overlook These Low-Risk High-Dividend Yielding Stocks
Via Talk Markets
Topics Stocks
Exposures US Equities
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.